158 related articles for article (PubMed ID: 35680605)
1. [Dose optimization: an individualized treatment strategy for chronic myeloid leukemia].
Chen YL; Zou J; Zhang YL; Li WM
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):436-440. PubMed ID: 35680605
[No Abstract] [Full Text] [Related]
2. Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.
Khorashad JS; Tantravahi SK; Yan D; Mason CC; Qiao Y; Eiring AM; Gligorich K; Hein T; Pomicter AD; Reid AG; Kelley TW; Marth GT; O'Hare T; Deininger MW
Leukemia; 2016 Nov; 30(11):2275-2279. PubMed ID: 27480386
[No Abstract] [Full Text] [Related]
3. Aggregates of Pseudogaucher Cells in a Pediatric Patient With Chronic Myeloid Leukemia.
Roldán Galiacho V; Moreno Gamiz M; Echebarrria-Barona A
J Pediatr Hematol Oncol; 2021 Aug; 43(6):224-225. PubMed ID: 34054044
[No Abstract] [Full Text] [Related]
4. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
5. The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.
Raanani P
Acta Haematol; 2016; 135(3):131-2. PubMed ID: 26535978
[No Abstract] [Full Text] [Related]
6. Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia.
Giona F; Malaspina F; Putti MC; Ladogana S; Mura R; Burnelli R; Vacca N; Rizzo L; Bianchi S; Moleti ML; Testi AM; Biondi A; Locatelli F; Saglio G; Foà R
Br J Haematol; 2020 Mar; 188(6):e101-e105. PubMed ID: 32087030
[No Abstract] [Full Text] [Related]
7. Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.
Angriman F; Gutierrez Acevedo MN; Rossi MS; Gimenez Conca AD; Otero V; Arbelbide JA; Michelángelo H
Turk J Haematol; 2015 Jun; 32(2):193-4. PubMed ID: 26316496
[No Abstract] [Full Text] [Related]
8. Imatinib-Associated Pneumocystis jirovecii Pneumonia in a Patient With Chronic Myeloid Leukemia.
Daw J; Thapa B; Chahine J; Lak H; Perez O; Nair R; Alomari M; Haddad A
Am J Ther; 2020; 27(4):e406-e409. PubMed ID: 31356343
[No Abstract] [Full Text] [Related]
9. Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.
Klil-Drori AJ; Yin H; Azoulay L; Harnois M; Gratton MO; Busque L; Assouline SE;
Haematologica; 2019 Jul; 104(7):e293-e295. PubMed ID: 30630987
[No Abstract] [Full Text] [Related]
10. Racial Differences in Survival of Elderly Adults with Chronic Myeloid Leukemia Before and After the Introduction of Imatinib in the United States.
Shah BK; Uprety D
J Am Geriatr Soc; 2016 Apr; 64(4):887-9. PubMed ID: 27100589
[No Abstract] [Full Text] [Related]
11. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
12. Imatinib mesylate inhibits proliferation and promotes apoptosis of chronic myeloid leukemia cells via STAT3 pathway.
Zhang H; Jin X; Diao Y; Wang L; Li N; Chen M
Panminerva Med; 2023 Mar; 65(1):118-119. PubMed ID: 31577092
[No Abstract] [Full Text] [Related]
13. Everything old is new again: the case for imatinib as frontline therapy in 2017.
Lee SG; Lipton JH
Clin Adv Hematol Oncol; 2017 Apr; 15(4):302-305. PubMed ID: 28591105
[No Abstract] [Full Text] [Related]
14. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
[No Abstract] [Full Text] [Related]
15. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer.
Geissler J; Sharf G; Cugurovic J; Padua R; Narbutas Š; Remic M; Venkatesh V
Leukemia; 2016 Dec; 30(12):2396-2397. PubMed ID: 27484147
[No Abstract] [Full Text] [Related]
17. Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
Sazawal S; Chikkara S; Singh K; Chaubey R; Chandra D; Mishra P; Mahapatra M; Seth T; Saxena R
Ann Diagn Pathol; 2017 Apr; 27():24-27. PubMed ID: 28325357
[TBL] [Abstract][Full Text] [Related]
18. Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
Singh S; Sharma PK
Indian J Pharmacol; 2016; 48(4):458-459. PubMed ID: 27756963
[TBL] [Abstract][Full Text] [Related]
19. External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy.
Qi F; Zhang X; Gale RP; Liu B; Huang J; Huang X; Jiang Q
Leukemia; 2023 Sep; 37(9):1922-1924. PubMed ID: 37516785
[No Abstract] [Full Text] [Related]
20. Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib.
Breccia M; Colafigli G; Molica M; De Angelis F; Quattrocchi L; Latagliata R; Mancini M; Diverio D; Alimena G
Br J Haematol; 2016 Jun; 173(6):945-6. PubMed ID: 26304741
[No Abstract] [Full Text] [Related]
[Next] [New Search]
